SCHEMBL5521119

SCHEMBL5521119

COc1ccc(COC(=O)Sc2nc(C)cc(C)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.45
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
POLB P06746 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
MMP13 P45452 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA1 P30542 1/20 0.42
MIF P14174 1/20 0.42
P2RX4 Q99571 1/20 0.41
HTT P42858 1/20 0.41
GLA P06280 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7268455 0.85 HPGD (0.48) KDM4EALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL9524342 0.83 HTT (0.43) MAOBKDM4EALDH1A1KMT2AMEN1
SCHEMBL7859572 0.81 MAPT (0.59) MAOBALDH1A1MAPTPOLBLMNA
Bicarbonate SCHEMBL11298239 0.75 KDM4E (0.60) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL10581498 0.74 ALDH1A1 (0.49) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL29009279 0.73 ALDH1A1 (0.53) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL11853555 0.72 ALDH1A1 (0.40) ALDH1A1KMT2AMAPTPOLBLMNA
SCHEMBL8645685 0.71 ALDH1A1 (0.54) MAOBKDM4EALDH1A1KMT2APOLB
SCHEMBL13034049 0.71 ALDH1A1 (0.54) MAOBALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL7332635 0.71 ADORA2A (0.41) MAOBKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
US-8481696-B2 Glycosylated glycopeptide antibiotic derivatives SHIONOGI & CO., LTD. (JP) 2013-07-09 US disclosed
US-8481696-B2 Glycosylated glycopeptide antibiotic derivatives SHIONOGI & CO., LTD. (JP) 2013-07-09 US disclosed
US-20100286364-A1 GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES SHIONOGI & CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286364-A1 GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES SHIONOGI & CO., LTD. (JP) 2010-11-11 US disclosed
US-20070161581-A1 Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas) MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-12 US disclosed
EP-1710248-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC EFFECTIVE AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) MEIJI SEIKA KAISHA LTD. (JP) 2006-10-11 EP disclosed
US-6583144-B2 Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia MEIJI SEIKA KAISHA, LTD. (JP) 2003-06-24 US disclosed
EP-0126587-A1 Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1984-11-28 EP disclosed
EP-0096392-A1 Novel aminoglycosides, process for production thereof and use thereof KOWA COMPANY, LTD. (JP) 1983-12-21 EP disclosed
EP-0094625-A1 Novel aminoglycosides and process for production thereof KOWA COMPANY, LTD. (JP) 1983-11-23 EP disclosed
US-4337335-A Transition metal salt complexes of polyamino organic compounds SCHERING CORPORATION (US) 1982-06-29 US disclosed
US-4296242-A Process for the preparation of chiral 3-amino-2-hydroxypropionic acid and N-blocked derivatives thereof SCHERING CORPORATION (US) 1981-10-20 US disclosed
US-4230847-A Aminoglycoside antibiotic compounds SCHERING CORPORATION (US) 1980-10-28 US disclosed
US-4180565-A ANTIBACTERIAL AGENTS, ANTIBIOTICS SCHERING CORPORATION (US) 1979-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161581-A1 Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas) RPS11, RPS18, MRPS17 MAOB 3092/4885KDM4E 4656/4885ALDH1A1 2089/4885
US-20100286364-A1 GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES CSGALNACT1, OGT, GALNT1 MAOB 4506/4885KDM4E 2334/4885ALDH1A1 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.